Skip to main content
Signal8
Launch Terminal

Kura Oncology, Inc. (KURA)

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Kura Oncology, Inc. logo

Kura Oncology, Inc.

NASDAQ:KURAHealthcare
-2.84%$10.26
AH$10.31+0.49%vs close
Mkt Cap$912.74M
Float78.14M
O/S88.96M
Vol
$ Vol
RVOL
Inst Own97.7%
SI18.3%
Earnings
Dilution
Kura Oncology, Inc. logoNASDAQ:KURA$10.26-2.84%
Phase Distribution
17 lead-sponsored trials·6 active·5 completed
Phase 17
Phase 1/22
Phase 25
Phase 31
Not applicable2
(6 more as collaborator)
Status Overview
Recruiting5
Active, not recruiting1
Completed5
Stopped4
Expanded access2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Recruiting

    Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

    Ziftomenib, Placebo

    Acute Myeloid Leukemia (AML)

    Enrollment
    1,300
    Start
    Sep 2025
    Primary Completion
    Nov 2031est.
    Completion
    Nov 2031est.
    NCT07007312
  • Phase 2
    Completed

    Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

    Tipifarnib

    Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) +2

    Enrollment
    63
    Start
    May 2015
    Primary Completion
    Dec 2020
    Completion
    Dec 2020
    NCT02383927
  • Phase 2
    Completed

    Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

    Tipifarnib

    Relapsed or Refractory Peripheral T-Cell Lymphoma

    Enrollment
    65
    Start
    Feb 2016
    Primary Completion
    Mar 2021
    Completion
    Mar 2021
    NCT02464228
  • Phase 2
    Terminated

    Tipifarnib in Subjects With Myelodysplastic Syndromes

    Tipifarnib

    Myelodysplastic Syndromes

    Enrollment
    16
    Start
    Jun 2016
    Primary Completion
    Aug 2018
    Completion
    Aug 2018
    NCT02779777
  • Phase 2
    Completed

    Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia

    Tipifarnib

    Leukemia, Myelomonocytic, Chronic

    Enrollment
    44
    Start
    Jan 2017
    Primary Completion
    Nov 2020
    Completion
    Nov 2020
    NCT02807272
  • Phase 2
    Completed

    Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

    Tipifarnib

    HRAS Gene Mutation, HNSCC

    Enrollment
    296
    Start
    Mar 2019
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT03719690
  • Phase 1/2
    Active, not recruiting

    First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

    Ziftomenib, Midazolam

    Advanced Malignant Neoplasm, Acute Myeloid Leukemia +5

    Enrollment
    263
    Start
    Sep 2019
    Primary Completion
    Oct 2028est.
    Completion
    Oct 2028est.
    NCT04067336
  • Phase 1/2
    Completed

    Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

    Tipifarnib, Alpelisib

    HNSCC

    Enrollment
    45
    Start
    Dec 2021
    Primary Completion
    Aug 2025
    Completion
    Aug 2025
    NCT04997902
  • Phase 1
    Terminated

    First-in-Human Study of KO-947 in Non-Hematological Malignancies

    KO-947

    Advanced Malignant Neoplasm

    Enrollment
    61
    Start
    Apr 2017
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT03051035
  • Phase 1
    Terminated

    Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

    Tipifarnib

    Advanced Solid Tumor

    Enrollment
    6
    Start
    May 2021
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT04865159
  • Phase 1
    Withdrawn

    Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

    Tipifarnib, Osimertinib

    NSCLC

    Enrollment
    0
    Start
    Feb 2023est.
    Primary Completion
    Jul 2027est.
    Completion
    Jul 2027est.
    NCT05693090
  • Phase 1
    Recruiting

    A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Ziftomenib, Venetoclax

    Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation +8

    Enrollment
    420
    Start
    Jul 2023
    Primary Completion
    Apr 2030est.
    Completion
    Apr 2030est.
    NCT05735184
  • Phase 1
    Recruiting

    Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Ziftomenib, Fludarabine

    AML, AML With Mutated NPM1 +10

    Enrollment
    171
    Start
    Feb 2024
    Primary Completion
    Dec 2026est.
    Completion
    Aug 2027est.
    NCT06001788
  • Phase 1
    Recruiting

    KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Darlifarnib, Cabozantinib

    Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC) +5

    Enrollment
    300
    Start
    Oct 2023
    Primary Completion
    Jan 2027est.
    Completion
    Apr 2027est.
    NCT06026410
  • Phase 1
    Recruiting

    A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

    ziftomenib, imatinib mesylate

    Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer +3

    Enrollment
    135
    Start
    Mar 2025
    Primary Completion
    Jun 2029est.
    Completion
    Jun 2030est.
    NCT06655246
  • Expanded access
    Available

    Expanded Access to Tipifarnib

    Tipifarnib

    HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT04809233
  • Expanded access
    Available

    Expanded Access to Ziftomenib

    ziftomenib

    Acute Lymphoblastic Leukemia, With KMT2A Rearrangements, Acute Myeloid Leukemia, With NPM1 Mutations +1

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT05738538
Search ClinicalTrials.gov for “Kura Oncology”